Abstract
Hypertension, the leading cause of mortality and the third largest cause of disability, is poorly controlled worldwide. The failure to control hypertension takes an unacceptable toll on patients and their families. In addition to the personal cost, to the individual patient, uncontrolled hypertension creates huge, avoidable economic burdens when viewed in terms of the general population. Almost one-half of patients drop out entirely from treatment within 1 year. This review summarizes key challenges related to hypertension management with special focus on patient compliance. Firstly, we will present consequences of poor blood pressure control. Secondly, methods of patient compliance assessment will be reviewed. Thirdly, we will present recent studies assessing adherence with hypertension treatment. Finally, we will review potential solutions to improve patient compliance and blood pressure control which are of crucial importance for reduction of hypertension-related morbidity and mortality.
Keywords: Hypertension, treatment, compliance, cardiovascular, stroke, ischaemic heart disease, high blood pressure, antihypertensive drugs, Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension), cardiovascular disease, therapeutic inertia, PATIENT COMPLIANCE, antihypertensive drug treat-ment, renin-angiotensin system, white-coat adher-ence, Arterial Hypertension, European Society of Hypertension, European Society of Cardiology, cardiovascular health, Control Hypertension Study
Current Vascular Pharmacology
Title: Improving Patient Compliance with Hypertension Treatment: Mission Possible?
Volume: 8 Issue: 6
Author(s): Marzena Chrostowska and Krzysztof Narkiewicz
Affiliation:
Keywords: Hypertension, treatment, compliance, cardiovascular, stroke, ischaemic heart disease, high blood pressure, antihypertensive drugs, Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension), cardiovascular disease, therapeutic inertia, PATIENT COMPLIANCE, antihypertensive drug treat-ment, renin-angiotensin system, white-coat adher-ence, Arterial Hypertension, European Society of Hypertension, European Society of Cardiology, cardiovascular health, Control Hypertension Study
Abstract: Hypertension, the leading cause of mortality and the third largest cause of disability, is poorly controlled worldwide. The failure to control hypertension takes an unacceptable toll on patients and their families. In addition to the personal cost, to the individual patient, uncontrolled hypertension creates huge, avoidable economic burdens when viewed in terms of the general population. Almost one-half of patients drop out entirely from treatment within 1 year. This review summarizes key challenges related to hypertension management with special focus on patient compliance. Firstly, we will present consequences of poor blood pressure control. Secondly, methods of patient compliance assessment will be reviewed. Thirdly, we will present recent studies assessing adherence with hypertension treatment. Finally, we will review potential solutions to improve patient compliance and blood pressure control which are of crucial importance for reduction of hypertension-related morbidity and mortality.
Export Options
About this article
Cite this article as:
Chrostowska Marzena and Narkiewicz Krzysztof, Improving Patient Compliance with Hypertension Treatment: Mission Possible?, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563799
DOI https://dx.doi.org/10.2174/157016110793563799 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dampening the Progression of Dementia
Current Neurovascular Research MicroRNAs in Platelet Biogenesis and Function: Implications in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Gene Polymorphism of Angiotensin II Type 1 and Type 2 Receptors
Current Pharmaceutical Design What Restricts the Clinical Use of Nicotinic Acid?
Current Vascular Pharmacology Mycophenolate Mofetil for the Treatment of Systemic Sclerosis
Letters in Drug Design & Discovery Role of NADPH Oxidase in Hypertension and Diabetic Nephropathy
Current Hypertension Reviews Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets Rationale of Statin Therapy in Septic Patients
Current Vascular Pharmacology Beneficial Effects of Lysosome-Modulating and Other Pharmacological and Nanocarrier Agents on Amyloid-beta-treated Cells
Current Pharmaceutical Biotechnology Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP)
Current Pharmaceutical Biotechnology Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis and Antihypertensive Activity of Novel Quinazolin-4(3H)-one Derivatives
Central Nervous System Agents in Medicinal Chemistry SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature
Current Pharmaceutical Design Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery Aquaporins in Sensory and Pain Transmission
Current Neuropharmacology PUFA for Prevention and Treatment of Dementia?
Current Pharmaceutical Design Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder
Current Alzheimer Research Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Considering Circadian Pattern of Blood Pressure in the Treatment of Hypertension via Chronotherapy: A Conducive or Maladroit Approach
Current Drug Targets